Skip to main content
IBO
NYSE Life Sciences

Impact BioMedical Shareholders Approve Zoar Merger With 99.97% of Votes Cast

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.17
Mkt Cap
$53.309M
52W Low
$2.43
52W High
$10.475
52W Position info
154% above low
Off High info
41% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

IBO has more than doubled off its 52-week low of $2.43.

Summary

Impact BioMedical stockholders voted overwhelmingly to approve the Zoar Limited merger at the November 13, 2026 special meeting, clearing the shareholder hurdle for a deal the cash-strapped company has called its main path forward.


Key Events · M&A and Partnerships · IBO

  • Zoar Merger Approved by Shareholders

    Stockholders approved and adopted the Merger and Share Exchange Agreement with Zoar Limited (f.k.a. Dr Ashleys Limited) by a vote of 7,713,011 for, 2,002 against and 197 abstain.

  • Quorum and Turnout

    At the Special Meeting, 7,715,210 shares were represented — 89.29% of the 8,640,000 shares outstanding and eligible to vote on the October 13, 2026 record date.

  • New Board and Charter Adopted

    Stockholders approved the Amended and Restated Memorandum and Articles of Association (7,600,533 for, 114,489 against) and elected eight directors: Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady and Chan Heng Fai Ambrose.

  • Auditor and Say-on-Pay Ratified

    Grassi & Co. Certified Public Accountants, P.C. was ratified as independent auditor for fiscal year 2026 (7,712,827 for), and named executive officer compensation passed on an advisory basis (7,506,873 for, 208,159 against).


Analysis · IBO · Life Sciences

The vote clears the last major shareholder hurdle for a deal in the works since June 2025 and the company's stated path out of its going-concern warning. With only $21,000 of cash reported at September 30, 2026, Impact BioMedical needs the Zoar combination to close to keep operating. The margin was overwhelming — 7,713,011 for versus 2,002 against — so the remaining risk is execution and closing, not shareholder approval. The same meeting also seated an eight-person board and ratified Grassi & Co. as auditor for 2026, putting the post-merger governance structure in place.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IBO was trading at $6.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $2.43 to $10.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IBO - Latest Insights

IBO
Nov 09, 2026, 4:50 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.33
Real-time Price: $6.17 info
Change: +$1.84 (+42%) info
Market Cap: $53.309M info